Samuel Giday, MD
Gastroenterology · Orlando, FLNPI 1598716110
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $2,029,192 of the $2,033,721 with a category attached, or 99.8%. Cook Incorporated accounts for 99.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $1,086,671 and has fallen 99.9% since, to $1,314 in 2025. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $15,525 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Incorporated$2M
- Adare Pharmaceuticals, Inc.$2K
- AbbVie$1K
- Medtronic$820
- Johnson & Johnson$188
- Madrigal Pharmaceuticals$150
- plus $811 from 16 others
Across 5 payments — averaging $10,555 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adare Pharmaceuticals, Inc.$53K
What the payments were for
- Royalty or licence$2,029,192100%
- Travel & lodging$1,9840%
- Food & beverage$2,5130%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Incorporated | 8 | $2,029,192 |
| Adare Pharmaceuticals, Inc. | 5 | $1,504 |
| AbbVie(2 entities) | 81 | $1,058 |
| Medtronic | 3 | $820 |
| Johnson & Johnson | 5 | $188 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Olympus America Inc. | 4 | $136 |
| Medical Device Business Services, Inc. | 1 | $117 |
| Angiodynamics, Inc. | 1 | $103 |
| Ipsen Biopharmaceuticals, Inc | 4 | $87 |
| Sanofi | 3 | $66 |
| Bristol Myers Squibb | 3 | $50 |
| Pentax Of America, Inc. | 1 | $48 |
| Novo Nordisk | 2 | $48 |
| QOL Medical, LLC | 2 | $39 |
| Braintree Laboratories, Inc. | 1 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Intra-sana Laboratories | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GI Genius$793
- REZDIFFRA$150
- Tremfya$139
- LINX Reflux Management System$117
How this compares
$2,033,721 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 77 | $379,881 |
| OcalivaObeticholic Acid | 13 | $121,491 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 327 | $55,975 |
| Mesalamine | 38 | $20,436 |
| LinzessLinaclotide | 14 | $17,331 |
| Pantoprazole Sodium | 1,179 | $16,913 |
| TrulancePlecanatide | 11 | $10,252 |
| Mesalamine ErMesalamine | 20 | $5,340 |
| Dexlansoprazole DrDexlansoprazole | 15 | $5,007 |
| Famotidine | 326 | $4,370 |
| Omeprazole | 297 | $3,531 |
| Ursodiol | 24 | $3,187 |
| CholestyramineCholestyramine (With Sugar) | 51 | $2,758 |
| Balsalazide Disodium | 23 | $2,722 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 179 | $2,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,058 | $397,21391 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $21 | $121,49113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu | $13 | $12,69427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Orlando
- Jennifer Seminerio-DiehlOrlando$1.1M
- Robert HawesOrlando$377K
- Jason KorenblitOrlando$373K
- Dennis YangOrlando$349K
- Muhammad HasanOrlando$312K
- Kenneth FeuerOrlando$118K
- Ahsan KhanOrlando$98K
- Ilan AharoniOrlando$56K
- Lukasz KwapiszMiami$1.2M
- Udayakumar NavaneethanSaint Petersburg$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.